Study of Utilization Patterns of Dimethyl Fumarate in Germany
What it found
We found no results in the registry or in papers.
This trial finished 9 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Dimethyl fumarate
Kelch-like ECH-associated protein 1 inhibitor
What it measured
Main measures
Proportion of dimethyl fumarate use that is prescribed "on-label" versus "off-label" in Germany
Up to 18 months after market introduction of dimethyl fumarate in Germany
Other measures (6)
Demographic characteristics of dimethyl fumarate users
Up to 18 months after market introduction of dimethyl fumarate in Germany
Prescription drug history of dimethyl fumarate users
Up to 18 months after market introduction of dimethyl fumarate in Germany
Duration of therapy in participants newly initiating dimethyl fumarate treatment
Up to 18 months after market introduction of dimethyl fumarate in Germany
Number of medical specialists prescribing dimethyl fumarate as identified according to specialty-specific billing codes at outpatient visits.
Up to 18 months after market introduction of dimethyl fumarate in Germany
Medical history of dimethyl fumarate users
Up to 18 months after market introduction of dimethyl fumarate in Germany
Concomitant medication use of dimethyl fumarate users
Up to 18 months after market introduction of dimethyl fumarate in Germany
Who could take part
MS (type not specified)
Key Inclusion Criteria: * New users of dimethyl fumarate will be included in the analysis Key Exclusion Criteria: * Patients for which data is not available for the 6 months period prior to the index date (baseline observational period) NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary objective of this study is to estimate the proportion of DMF use that is prescribed "on-label" versus "off-label". The secondary objectives are: To describe the demographic characteristics and medical history of DMF users; To describe prescription drug history and concomitant medication use of DMF users; To describe the duration of therapy in participants newly initiating DMF treatment; To describe the medical specialties of DMF prescribers.
Loading reviews and guidelines…
Related trials
- A Study to Evaluate Long-Term Safety of Vumerity and Tecf…
Running, not recruiting
Still running
- TDM-MS
Phase 4 · Status unknown
No result found
- Effects of Dimethyl Fumarate on Cognitive Performance and…
Completed
No result found
- STATURE
Status unknown
No result found
- Study to Compare GI Tolerability Following Oral Administr…
Phase 1 · Completed
No result found
- Teriflunomide Tecfidera LMCE
Completed
Result in a paper, not read yet
History
Started
Dec 2016
Main results due
Mar 2017
Finished
Mar 2017
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error